Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Meniere Disease Pipeline Therapeutics Development Review, H2 2016.

Wednesday, September 21, 2016 1:56
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Global Markets Direct’s, ‘Meniere Disease – Pipeline Review, H2 2016′, provides an overview of the Meniere Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meniere Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

 

Complete report on Meniere Disease – Pipeline Review, H2 2016 addition with 18 market data tables and 11 figures, spread across 48 pages is http://www.rnrmarketresearch.com/meniere-disease-pipeline-review-h2-2016-market-report.html

 

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

 

Drugs Profile Discussed in this Research:

betamethasone valerate ER, dexamethasone acetate SR, latanoprost, OR-105, QPHL-2, SPI-1005 

 

Companies Discussed/Mentioned in this Research:

Orbis Biosciences Inc , Otonomy, Inc.
Quark Pharmaceuticals, Inc.
Sound Pharmaceuticals, Inc.
Synphora AB

 

Inquire before buying for this report

http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=692214. (This is a premium report price at US$2000 for a single user PDF license).

 

Scope:

  • The report provides a snapshot of the global therapeutic landscape of Meniere Disease
  • The report reviews pipeline therapeutics for Meniere Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Meniere Disease therapeutics and enlists all their major and minor projects
  • The report assesses Meniere Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

Reasons to buy

  •    Gain strategically significant competitor information, analysis, and insights to formulate effective              R&D strategies

  •      Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  •     Identify and understand important and diverse types of therapeutics under development for Meniere Disease

  •    Identify potential new clients or partners in the target demographic

  •    Develop strategic initiatives by understanding the focus areas of leading companies

  •     Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

  •    Devise corrective measures for pipeline projects by understanding Meniere Disease pipeline depth and focus of Indication therapeutics

  •     Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  •     Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.